AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Financial Results | Bristol-Myers Squibb 2025 Half-Year Revenue USD 23470.00 Million Net Income USD 3775.00 Million
ByAinvest
Thursday, Jul 31, 2025 10:00 pm ET1min read
Bristol-Myers Squibb(BMY) posted the Q2 of its 2025 financial results on 7/31/2025, reporting total revenue of USD 23470.00 million in the first half of the year, down 2.48% from USD 24066.00 million year over year, reporting net income of USD 3775.00 million in the first half of the year, compare with the net income of USD -10224.00 million in the same period last year. The EPS is USD 1.85 in the first half of the year, compare with USD -5.05 last period.
[Detailed Data]
| Million USD | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Total Revenue | 12269.00 | 11201.00 | 12342.00 | 11892.00 |
| Cost of Sales | 3372.00 | 3033.00 | 4812.00 | 2957.00 |
| Gross Profit | 8897.00 | 8168.00 | 7530.00 | 8935.00 |
| Total Operating Expenses | 7125.00 | 5198.00 | 7355.00 | 7259.00 |
| Operating Income | 1772.00 | 2970.00 | 175.00 | 1676.00 |
| Net Income | 1313.00 | 2462.00 | 76.00 | 1215.00 |
| Net Income Attributable to Common Shareholders | 1310.00 | 2456.00 | 72.00 | 1211.00 |
| EPS(USD) | 0.64 | 1.21 | 0.04 | 0.6 |
[Company Profile]
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, the company changed its name to Bristol-Myers Squibb Company as a result of a merger. The company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The company expect that acquisitions of Celgene and MyoKardia will further position the company as a leading biopharmaceutical company, expanding their oncology, hematology, immunology and cardiovascular portfolios with several near-term assets and additional external partnerships.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet